Hi rgc68, tend to agree with you here.
The way things may shape up is that HIV becomes the main game for BIT225 - with the positive HCV results an added benefit for co-infected patients.
The ability of BIT225 to target the 'HIV reserviors' seems to be peculiar to this drug???
Anyway an update on the HIV trial would be nice, although BIT have been historically laggards in the communication business (although they didn't do a bad job in getting the oppies converted)
bluebush
victrelis approved in austr, page-7
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
